	US 12,227,582 B2
	CD137 agonist antibodies and uses thereof
Aaron Kurtzman, South San Francisco, CA (US); Hieu Tran, South San Francisco, CA (US); and Shihao Chen, South San Francisco, CA (US)
Assigned to QLSF BIOTHERAPEUTICS INC., South San Francisco, CA (US)
Appl. No. 17/275,153
Filed by QLSF BIOTHERAPEUTICS INC., South San Francisco, CA (US)
PCT Filed Jan. 2, 2020, PCT No. PCT/US2020/012080 § 371(c)(1), (2) Date Mar. 10, 2021, PCT Pub. No. WO2020/142624, PCT Pub. Date Jul. 9, 2020.
Claims priority of provisional application 62/787,509, filed on Jan. 2, 2019.
Prior Publication US 2022/0064314 A1, Mar. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)]

17 Claims

1. An isolated anti-CD137 agonist antibody, or an antigen-binding portion thereof, comprising:

a heavy chain variable region CDR1 comprising SEQ ID NO:29, a heavy chain variable region CDR2 comprising SEQ ID NO:30, and a heavy chain variable region CDR3 comprising SEQ ID NO:31; and

a light chain variable region CDR1 comprising SEQ ID NO:26, a light chain variable region CDR2 comprising SEQ ID NO:27, and a light chain variable region CDR3 comprising SEQ ID NO:28;

wherein said antibody or portion specifically binds to human CD137.